RxDoctor Payments Data

Christopher McCarty, MD

Cardiovascular Disease · Ladson, SCNPI 1912916099

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,421 of the $12,819 with a category attached, or 81.3%. 41 manufacturers reported payments, led by Medtronic at 33.2% of the total. Reporting peaked in 2019 at $4,209 and has fallen 55.9% since, to $1,856 in 2025.

$12,819in general payments, 2019–2025

Across 508 payments — averaging $25.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abbott$1K
  • Boston Scientific$913
  • E.r. Squibb & Sons, L.L.C.$893
  • Johnson & Johnson$841
  • AstraZeneca$623
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$2,38619%
  • Food & beverage$10,42181%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,819 in reported general payments places this provider in the 85th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$309,955
Medicare patients
879
Services billed
3,556

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$92,058
JardianceEmpagliflozin78$73,287
EntrestoSacubitril/Valsartan29$36,733
XareltoRivaroxaban32$29,757
FarxigaDapagliflozin Propanediol23$18,589
BrilintaTicagrelor25$12,948
Metoprolol Succinate128$1,365
Diltiazem 24hr Er (Cd)Diltiazem Hcl35$912
Atorvastatin Calcium103$862
ClopidogrelClopidogrel Bisulfate82$767
Isosorbide Mononitrate ErIsosorbide Mononitrate38$722
Isosorbide Dinitrate17$721
Rosuvastatin Calcium26$634
Amiodarone Hcl28$589
Furosemide116$539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$383$92,05881 claims
Boehringer IngelheimJardiance$388$73,28778 claims
NovartisEntresto$515$36,73329 claims
AstraZenecaFarxiga, Brilinta$623$31,53748 claims
Johnson & JohnsonXarelto$841$29,75732 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Ladson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →